ANI Pharmaceuticals, Inc. (ANIP) Stock AnalysisANIPANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units, Rare Disease and Brands. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel and ILUVIEN. The Brands unit includes a portfolio of over 20 branded products that are principally sold in genericized markets. Its Generics and Other segment consists of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

ANI Pharmaceuticals Inc is a good buy right now due to its recent FDA approval for Everolimus Tablets, which has a market potential of approximately $123 million. The stock's current price of $73.89 is below the average analyst price target of $99.75, indicating potential upside. Additionally, the forward P/E ratio is notably low at 7.12, suggesting the stock may be undervalued. However, a risk to consider is the significant insider selling, which has increased by 14497.26% over the last month, indicating potential concerns about the company's future performance.

3 analysts cover ANIP: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 115.00.